NASDAQ:DERM Journey Medical (DERM) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free DERM Stock Alerts $3.89 +0.20 (+5.42%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$3.60▼$3.9850-Day Range N/A52-Week Range$1.02▼$8.11Volume122,669 shsAverage Volume177,373 shsMarket Capitalization$72.00 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Journey Medical alerts: Email Address Journey Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside118.5% Upside$8.50 Price TargetShort InterestHealthy1.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 21 Articles This WeekInsider TradingAcquiring Shares$169,300 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.83) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.68 out of 5 starsMedical Sector460th out of 939 stocksPharmaceutical Preparations Industry221st out of 433 stocks 3.5 Analyst's Opinion Consensus RatingJourney Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Journey Medical has a forecasted upside of 118.5% from its current price of $3.89.Amount of Analyst CoverageJourney Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.23% of the float of Journey Medical has been sold short.Short Interest Ratio / Days to CoverJourney Medical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Journey Medical has recently increased by 22.98%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldJourney Medical does not currently pay a dividend.Dividend GrowthJourney Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DERM. Previous Next 2.5 News and Social Media Coverage News SentimentJourney Medical has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Journey Medical this week, compared to 6 articles on an average week.Search Interest17 people have searched for DERM on MarketBeat in the last 30 days. This is an increase of 113% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Journey Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Journey Medical insiders have bought 1,742.62% more of their company's stock than they have sold. Specifically, they have bought $169,300.00 in company stock and sold $9,188.00 in company stock.Percentage Held by Insiders19.42% of the stock of Journey Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.25% of the stock of Journey Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Journey Medical are expected to grow in the coming year, from ($0.83) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Journey Medical is -11.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Journey Medical is -11.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJourney Medical has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Journey Medical Stock (NASDAQ:DERM)Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Read More DERM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DERM Stock News HeadlinesMarch 26, 2024 | insidertrades.comJourney Medical Co. (NASDAQ:DERM) CEO Acquires $34,800.00 in StockMarch 26, 2024 | insidertrades.comJourney Medical Co. (NASDAQ:DERM) Director Justin Adam Smith Buys 30,000 SharesMarch 28, 2024 | Behind the Markets (Ad)The Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.March 25, 2024 | finance.yahoo.comDirector Justin Smith Acquires 30,000 Shares of Journey Medical Corp (DERM)March 25, 2024 | americanbankingnews.comJourney Medical Co. (NASDAQ:DERM) Expected to Earn FY2028 Earnings of $0.51 Per ShareMarch 23, 2024 | seekingalpha.comJourney Medical Corporation (DERM) Q4 2023 Earning Call TranscriptMarch 23, 2024 | finance.yahoo.comJourney Medical Full Year 2023 Earnings: EPS Misses ExpectationsMarch 22, 2024 | uk.investing.comJourney Medical Corp (DERM)March 28, 2024 | Behind the Markets (Ad)The Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.March 22, 2024 | finance.yahoo.comQ4 2023 Journey Medical Corp Earnings CallMarch 21, 2024 | investorplace.comDERM Stock Earnings: Journey Medical Beats EPS, Beats Revenue for Q4 2023March 21, 2024 | msn.comJourney Medical GAAP EPS of -$0.21 misses by $0.02, revenue of $79.18M beats by $0.21MMarch 21, 2024 | benzinga.comRecap: Journey Medical Q4 EarningsMarch 21, 2024 | globenewswire.comJourney Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 20, 2024 | benzinga.comJourney Medical Earnings PreviewMarch 20, 2024 | money.usnews.comJourney Medical CorpMarch 20, 2024 | americanbankingnews.comJourney Medical Co. (NASDAQ:DERM) Short Interest Up 6.8% in FebruaryMarch 19, 2024 | msn.comJourney Medical announces U.S. FDA acceptance of NDA for its rosacea treatmentMarch 19, 2024 | americanbankingnews.comJourney Medical (DERM) Scheduled to Post Quarterly Earnings on ThursdayMarch 18, 2024 | globenewswire.comJourney Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaMarch 17, 2024 | msn.comWater’s WoeMarch 17, 2024 | dailymail.co.ukFrom celery to parsley - all the foods that can trigger a nasty skin condition if you chop them in the sun...after doctor warns of surge in 'margarita burn'March 16, 2024 | ca.finance.yahoo.comFBIO Apr 2024 2.500 callMarch 15, 2024 | msn.comMatch Day in Lubbock sees 100% of TTUHSC students matched for residency programMarch 15, 2024 | globenewswire.comJourney Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024March 13, 2024 | forbes.comDermatology Marketing: How To Navigate The Changing LandscapeMarch 13, 2024 | globenewswire.comJourney Medical Corporation to Participate in the 36th Annual ROTH ConferenceSee More Headlines Receive DERM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Journey Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DERM Previous SymbolNASDAQ:DERM CUSIPN/A CIK1867066 Webjourneymedicalcorp.com Phone480-434-6670FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$8.50 Low Stock Price Target$8.50 Potential Upside/Downside+118.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,850,000.00 Net Margins-4.87% Pretax Margin-15.33% Return on Equity-46.48% Return on Assets-4.99% Debt Debt-to-Equity RatioN/A Current Ratio0.92 Quick Ratio0.69 Sales & Book Value Annual Sales$79.18 million Price / Sales0.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.96 per share Price / Book4.05Miscellaneous Outstanding Shares18,510,000Free Float14,914,000Market Cap$72.00 million OptionableN/A Beta0.83 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Lindsay Allan Rosenwald (Age 69)Executive Chairman Comp: $50kMr. Claude Maraoui (Age 57)Founder, President, CEO & Director Comp: $820.3kMr. Joseph M. Benesch (Age 57)Interim CFO & Corporate Controller Mr. Andrew J. ZwibleVice President of OperationsMr. Ramsey Alloush (Age 38)General Counsel & Company Secretary Mr. Robert Nevin (Age 56)Chief Commercial Officer Jaclyn JaffeSenior Director of Corporate OperationsMore ExecutivesKey CompetitorsKezar Life SciencesNASDAQ:KZRKronos BioNASDAQ:KRONMediciNovaNASDAQ:MNOVEagle PharmaceuticalsNASDAQ:EGRXTempest TherapeuticsNASDAQ:TPSTView All CompetitorsInsiders & InstitutionsLindsay A Md RosenwaldBought 10,000 shares on 3/25/2024Total: $30,400.00 ($3.04/share)Claude MaraouiBought 10,000 shares on 3/22/2024Total: $34,800.00 ($3.48/share)Justin Adam SmithBought 30,000 shares on 3/22/2024Total: $104,100.00 ($3.47/share)Vanguard Group Inc.Bought 56,781 shares on 3/11/2024Ownership: 0.699%Virtu Financial LLCBought 26,586 shares on 2/26/2024Ownership: 0.144%View All Insider TransactionsView All Institutional Transactions DERM Stock Analysis - Frequently Asked Questions Should I buy or sell Journey Medical stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Journey Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DERM shares. View DERM analyst ratings or view top-rated stocks. What is Journey Medical's stock price target for 2024? 1 Wall Street analysts have issued 1-year price targets for Journey Medical's shares. Their DERM share price targets range from $8.50 to $8.50. On average, they predict the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 118.5% from the stock's current price. View analysts price targets for DERM or view top-rated stocks among Wall Street analysts. How have DERM shares performed in 2024? Journey Medical's stock was trading at $4.82 on January 1st, 2024. Since then, DERM shares have decreased by 19.3% and is now trading at $3.89. View the best growth stocks for 2024 here. Are investors shorting Journey Medical? Journey Medical saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 79,200 shares, an increase of 23.0% from the February 29th total of 64,400 shares. Based on an average daily volume of 215,500 shares, the short-interest ratio is presently 0.4 days. Currently, 1.2% of the shares of the company are sold short. View Journey Medical's Short Interest. When is Journey Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our DERM earnings forecast. What other stocks do shareholders of Journey Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Journey Medical investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), Karyopharm Therapeutics (KPTI), Pfizer (PFE), AT&T (T), Exelixis (EXEL) and ImmunoGen (IMGN). When did Journey Medical IPO? Journey Medical (DERM) raised $39 million in an IPO on Friday, November 12th 2021. The company issued 3,520,000 shares at a price of $10.00-$12.00 per share. Who are Journey Medical's major shareholders? Journey Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.70%), Vanguard Group Inc. (0.70%), Virtu Financial LLC (0.14%), Northern Trust Corp (0.09%) and Citadel Advisors LLC (0.06%). Insiders that own company stock include Claude Maraoui, Joseph Benesch, Justin Adam Smith and Lindsay A Md Rosenwald. View institutional ownership trends. How do I buy shares of Journey Medical? Shares of DERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DERM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Journey Medical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.